Titan Medical Inc (TMDIF)

[Md4Ob]

As your points are valuable and well taken, as a physician, biotechs do generate revenue in fashions rather exponentially. However, the prices that they are paid are simultaneously paid in dividends to those receiving such novel medications as Rituxan® which has made diseases like Non-Hodgkin's Lymphoma into a chronic disease state and Momelotinib, a medication that is currently being tested by Gilead against pancreatic cancer, and Ziopharm Oncology's Ad-RTS-IL-12 which is still in testing against Melanoma, Breast Cancer and potentially Glioblastoma. I entertain that these companies have been or will be paid handsomely for their efforts. The costs to research those medications is high and the patents are rather short lived. As I have represented before, I think that SPORT has incredible potential which is being stifled by a management team that may potentially get the product to market a day late and a dollar short. I am still long on TITXF but my legs are growing tired. I have owned TITXF since the days when AMADEUS was assured and we all know what became of that technology. In terms of patient safety and outcome, there are no metrics to indicate that SPORT can outperform ISRG Xi or Si. Again, my fear is that hospitals will actively trade in their Si equipment for Xi platforms with ISRG single port technology to be released forthwith.